Amezalpat received fast track designation from the FDA for the treatment of patients with hepatocellular carcinoma.

Fast Track Designation highlights potential of amezalpat to address unmet need for patients with HCC. Amezalpat builds ...

China: A recent study published in the Annals of Hepatology has emphasized the influence of age on hepatocellular carcinoma ...

Hepatocellular carcinoma (HCC) is an aggressive disease that accounts for 80%-90% of all primary liver cancers. Previous findings have shown fibroblast growth factor 19 (FGF-19) to be overexpressed in ...

SGLT-2 inhibitors vs DPP-4 inhibitors were associated with a reduced risk for liver cirrhosis among patients with type 2 diabetes.

A new study reveals that even low-dose, chronic exposure to air pollution can trigger liver inflammation, fibrosis, and metabolic disruptions, increasing the risk of fatty liver disease and other ...

Investigator Award has been awarded to two surgeon-scientists at the National Cancer Centre Singapore (NCCS) to pursue novel research in liver cancer and head and neck cancers. Globally, liver cancer ...

On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...

Hundreds of a people who have chronic liver disease are being helped by an NHS trust's service that helps them attend vital ...

They evaluate its efficacy in natural aging and in reducing progression from steatotic liver disease to hepatocellular carcinoma, using mouse models. Lee et al. demonstrate that Ginkgolide B ...

Dr. Waqqas Tai is a cancer doctor who often shares health advice online. He recently revealed what the five most "lethal" ...